Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pilulka Lekarny AS's enterprise value is Kč333.3 Mil.
Pilulka Lekarny AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was Kč19.6 Mil. Therefore, Pilulka Lekarny AS's EV-to-EBITDA for today is 17.02.
The historical rank and industry rank for Pilulka Lekarny AS's EV-to-EBITDA or its related term are showing as below:
During the past 9 years, the highest EV-to-EBITDA of Pilulka Lekarny AS was 39.94. The lowest was -3929.59. And the median was -90.63.
XPRA:PINK's EV-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 10.09 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Pilulka Lekarny AS (XPRA:PINK) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pilulka Lekarny AS's PE Ratio (TTM) for today is calculated as:
Pilulka Lekarny AS's share price for today is Kč110.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pilulka Lekarny AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was Kč-14.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Pilulka Lekarny AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pilulka Lekarny AS EV-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Pilulka Lekarny AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pilulka Lekarny AS EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pilulka Lekarny AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pilulka Lekarny AS's EV-to-EBITDA falls into.
Pilulka Lekarny AS's current Enterprise Value is Kč333.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pilulka Lekarny AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was Kč19.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pilulka Lekarny AS (XPRA:PINK) has a EV-to-EBITDA of 17.02 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pilulka Lekarny AS. According to the industry distribution chart, Pilulka Lekarny AS ranks #999999 out of 523 companies in the Healthcare Providers & Services industry.
Is Pilulka Lekarny AS's EV-to-EBITDA too high?
Pilulka Lekarny AS's current EV-to-EBITDA is 17.02. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.09. Pilulka Lekarny AS's value of 17.02 is 68.7% above this industry median. Based on the distribution chart, Pilulka Lekarny AS ranks #999999 out of 523 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pilulka Lekarny AS has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pilulka Lekarny AS ranks #999999 out of 523 companies for EV-to-EBITDA. This places Pilulka Lekarny AS in the lower half of its industry. The industry median EV-to-EBITDA is 10.09. Pilulka Lekarny AS's value of 17.02 is 68.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.09, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pilulka Lekarny AS's current EV-to-EBITDA of 17.02 is 68.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Pilulka Lekarny AS. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pilulka Lekarny AS's current EV-to-EBITDA is 17.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč100.01, compared to a current price of Kč110.00 — trading 10% above its estimated fair value. The current EV-to-EBITDA is 17.02 and 68.7% above the Healthcare Providers & Services industry median of 10.09. Pilulka Lekarny AS's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current EV-to-EBITDA is 17.02 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?
Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be overvalued.
The current stock price of Kč110.00 is trading 10% above its estimated GF Value™ of Kč100.01.
GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.
Key valuation signals for XPRA:PINK:
EV-to-EBITDA: 17.02
GF Value™: Kč100.01 vs. price of Kč110.00 (10% above fair value)
Industry Position: 68.7% above the Healthcare Providers & Services median (#999999 of 523)
No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
49GF Score
Get the complete analysis for XPRA:PINK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPRA:PINK has been successfully added to your 
